Data on CDK4/6 inhibitors in adjuvant setting in early HR+/HER2-#breastcancer looks promising. Sharing an article that puts trials data into clinical practice perspective, suggesting how to choose wisely between CDK4/6i.
Data on CDK4/6 inhibitors in adjuvant setting in early HR+/HER2-#breastcancer looks promising. Sharing an article that puts trials data into clinical practice perspective, suggesting how to choose wisely between CDK4/6i.
